Cargando…

Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways

OBJECTIVE: Pancreatic cancer is one of the most lethal types of cancer with a 5-year survival rate of ~5%. Histone deacetylases (HDACs) participate in many cellular processes, including carcinogenesis, and pharmacological inhibition of HDACs has emerged as a potential therapeutic strategy. In this s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yi-Jin, Wang, Wen-Hung, Wu, Wan-Yu, Hsu, Chia-Chi, Wei, Ling-Rung, Wang, Sheng-Fan, Hsu, Ya-Wen, Liaw, Chih-Chuang, Tsai, Wan-Chi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567660/ https://www.ncbi.nlm.nih.gov/pubmed/28829799 http://dx.doi.org/10.1371/journal.pone.0183368

Ejemplares similares

Histone deacetylase inhibitor AR-42 and achiral analogues kill malaria parasites in vitro and in mice
por: Chua, Ming Jang, et al.
Publicado: (2021)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

The Effect of a Histone Deacetylase Inhibitor (AR-42) and Zoledronic Acid on Adult T-Cell Leukemia/Lymphoma Osteolytic Bone Tumors
por: Elshafae, Said M., et al.
Publicado: (2021)

A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4(+) T-cells
por: Mates, Jessica M., et al.
Publicado: (2015)

Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42()()
por: Henderson, Sally E., et al.
Publicado: (2016)

Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas
por: Welling, D. Bradley, et al.
Publicado: (2021)

Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia
por: Guzman, Monica L., et al.
Publicado: (2014)

A Novel Histone Deacetylase Inhibitor Exhibits Antitumor Activity via Apoptosis Induction, F-Actin Disruption and Gene Acetylation in Lung Cancer
por: Tang, Yen-An, et al.
Publicado: (2010)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

NBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity
por: Huang, Wei-Jan, et al.
Publicado: (2012)

On atmospheric $^{39}Ar$ and $^{42}Ar$ abundance
por: Cennini, P, et al.
Publicado: (1995)

The histone deacetylase Hos2 forms an Hsp42-dependent cytoplasmic granule in quiescent yeast cells
por: Liu, I-Chun, et al.
Publicado: (2012)

Mitochondrial Apoptosis and FAK Signaling Disruption by a Novel Histone Deacetylase Inhibitor, HTPB, in Antitumor and Antimetastatic Mouse Models
por: Shieh, Jiunn-Min, et al.
Publicado: (2012)

The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo
por: Lucas, David M., et al.
Publicado: (2010)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities
por: Zhao, Na, et al.
Publicado: (2020)

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

Characterization of 42 Microsatellite Markers from Poison Ivy, Toxicodendron radicans (Anacardiaceae)
por: Hsu, Tsai-Wen, et al.
Publicado: (2013)

Histone Deacetylase Inhibitors Downregulate Calcium Pyrophosphate Crystal Formation in Human Articular Chondrocytes
por: Chang, Chi-Ching, et al.
Publicado: (2022)

Design, synthesis, and antitumor evaluation of histone deacetylase inhibitors with l-phenylglycine scaffold
por: Zhang, Yingjie, et al.
Publicado: (2015)

Histone deacetylase 3 binds to and regulates the GCMa transcription factor
por: Chuang, Hsiao-Ching, et al.
Publicado: (2006)

Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cells
por: Yang, Wen-Bin, et al.
Publicado: (2021)

Efficacy of Azatyrosine-Phenylbutyric Hydroxamides, a Histone Deacetylase Inhibitor, on Chemotherapy-Induced Gastrointestinal Mucositis
por: Liao, Po-Lin, et al.
Publicado: (2019)

AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma
por: Zhu, Yuxuan, et al.
Publicado: (2019)

Methylation-directed acetylation of histone H3 regulates developmental sensitivity to histone deacetylase inhibition
por: Huang, Li-Yao, et al.
Publicado: (2021)

Interferon Regulatory Factor-8 Is Important for Histone Deacetylase Inhibitor-Mediated Antitumor Activity
por: Banik, Debarati, et al.
Publicado: (2012)

Antitumor Action of a Novel Histone Deacetylase Inhibitor, YF479, in Breast Cancer()
por: Zhang, Tao, et al.
Publicado: (2014)

Inhibition of Notch Signaling Enhances Antitumor Activity of Histone Deacetylase Inhibitor LAQ824
por: Mei, Qinglang, et al.
Publicado: (2023)

Carbocisteine Improves Histone Deacetylase 2 Deacetylation Activity via Regulating Sumoylation of Histone Deacetylase 2 in Human Tracheobronchial Epithelial Cells
por: Song, Yun, et al.
Publicado: (2019)

Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach
por: Wang, Lihui, et al.
Publicado: (2015)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Histone deacetylase III interactions with BK polyomavirus large tumor antigen may affect protein stability
por: Hsu, Yueh-Han, et al.
Publicado: (2023)

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors
por: Han, Yu, et al.
Publicado: (2022)

New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells
por: Gueugnon, Fabien, et al.
Publicado: (2014)

Diversity, evolution and expression profiles of histone acetyltransferases and deacetylases in oomycetes
por: Wang, Xiao-Wen, et al.
Publicado: (2016)

Chidamide, a histone deacetylase inhibitor, inhibits autophagy and exhibits therapeutic implication in chronic lymphocytic leukemia
por: Kong, Yi-Lin, et al.
Publicado: (2020)

Histone Deacetylase 6 Knockout Mice Exhibit Higher Susceptibility to Influenza A Virus Infection
por: Zanin, Mark, et al.
Publicado: (2020)

Histone deacetylase 3, not histone deacetylase 2, interacts with the major immediate early locus of human cytomegalovirus
por: Huang, Ying, et al.
Publicado: (2011)

Characterization of a novel androgen receptor (AR) coregulator RIPK1 and related chemicals that suppress AR-mediated prostate cancer growth via peptide and chemical screening
por: Hsu, Cheng-Lung, et al.
Publicado: (2017)

Design of Diarylheptanoid Derivatives as Dual Inhibitors Against Class IIa Histone Deacetylase and β-amyloid Aggregation
por: Chen, Liang-Chieh, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ge0rjfd4h13cfp6ef0u1r5l92d